相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brentuximab vedotin in combination with sequential procarbazine, cyclophosphamide and prednisolone for the management of Hodgkin's lymphoma-associated vanishing bile duct syndrome (VBDS) with severe obstructive liver failure
Min Fong et al.
BMJ CASE REPORTS (2019)
Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review
Mena Bakhit et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Single-Agent Brentuximab as Bridging Therapy for Hodgkin Lymphoma Patients With Hepatic Impairment
Arjun Gupta et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Ajay K. Gopal et al.
BLOOD (2015)
Vanishing Bile Duct Syndrome in a Hodgkin's Lymphoma Patient with Fatal Outcome Despite Lymphoma Remission
Aamer Aleem et al.
SAUDI JOURNAL OF GASTROENTEROLOGY (2013)
Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: Statistical analysis of all published cases and literature review
Ari Ballonoff et al.
ACTA ONCOLOGICA (2008)
分享论文
